Corporate News
Therma Bright Successfully Up-lists to the OTCQB Venture Market Under Symbol TBRIF
Toronto, Ontario–(Newsfile Corp. – September 14, 2021) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19
Therma Bright Provides Update on FDA-EUA Application Process
Toronto, Ontario–(Newsfile Corp. – September 1, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen
Therma Bright Finalizes Agreement with Afero for Its Smart-Enabled AcuVid(TM) Saliva Test
Toronto, Ontario–(Newsfile Corp. – August 5, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its ‘smart-enabled’ AcuVid™ COVID-19 Rapid Antigen Saliva
Therma Bright Files Application to the OTCQB and DTC Clearing
Toronto, Ontario–(Newsfile Corp. – July 29, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen
Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results
Toronto, Ontario–(Newsfile Corp. – July 22, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen
Therma Bright to Test AcuVid(TM) on the Highly Contagious COVID-19 Delta Variant, Company Completes Brazilian Clinical Study for Final FDA EUA Submission
Toronto, Ontario–(Newsfile Corp. – June 24, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva
Therma Bright Reports Performance of Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test from Brazilian Clinical Study
Toronto, Ontario–(Newsfile Corp. – June 17, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ COVID-19 Rapid Antigen Saliva
Why There is Still a Dire Need for COVID-19 Testing
While the tide has turned in many countries in battle against the COVID-19, the global pandemic is far from over in countries like India, for
Therma Bright Provides Update on Brazilian Clinical Study
Company advances final validation efforts of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Toronto, Ontario–(Newsfile Corp. – May 27, 2021) – Therma Bright Inc. (TSXV: THRM)
Therma Bright Secures Development and Manufacturing Partner for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
K-One MediTech To Begin Production of CE approved 15-Minute Antigen Test Solution Toronto, Ontario–(Newsfile Corp. – May 21, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma”
Therma Bright Enters into Agreement to Distribute a 15 Minute Rapid COVID-19 Antibody Test
Toronto, Ontario–(Newsfile Corp. – May 6, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ COVID-19 Rapid Antigen Saliva
Newsletter: Our Vision For A Better & Brighter Future
Smart-enabled AcuVid™ Antigen Test On April 28, 2021, Therma Bright announced a memorandum of understanding (MOU) agreement to incorporate a secure tracking technology into its
Therma Bright Successfully Up-lists to the OTCQB Venture Market Under Symbol TBRIF
Toronto, Ontario–(Newsfile Corp. – September 14, 2021) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19
Therma Bright Provides Update on FDA-EUA Application Process
Toronto, Ontario–(Newsfile Corp. – September 1, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen
Therma Bright Finalizes Agreement with Afero for Its Smart-Enabled AcuVid(TM) Saliva Test
Toronto, Ontario–(Newsfile Corp. – August 5, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its ‘smart-enabled’ AcuVid™ COVID-19 Rapid Antigen Saliva
Therma Bright Files Application to the OTCQB and DTC Clearing
Toronto, Ontario–(Newsfile Corp. – July 29, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen
Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results
Toronto, Ontario–(Newsfile Corp. – July 22, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen
Therma Bright to Test AcuVid(TM) on the Highly Contagious COVID-19 Delta Variant, Company Completes Brazilian Clinical Study for Final FDA EUA Submission
Toronto, Ontario–(Newsfile Corp. – June 24, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva
Therma Bright Reports Performance of Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test from Brazilian Clinical Study
Toronto, Ontario–(Newsfile Corp. – June 17, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ COVID-19 Rapid Antigen Saliva
Why There is Still a Dire Need for COVID-19 Testing
While the tide has turned in many countries in battle against the COVID-19, the global pandemic is far from over in countries like India, for
Therma Bright Provides Update on Brazilian Clinical Study
Company advances final validation efforts of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Toronto, Ontario–(Newsfile Corp. – May 27, 2021) – Therma Bright Inc. (TSXV: THRM)
Therma Bright Secures Development and Manufacturing Partner for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
K-One MediTech To Begin Production of CE approved 15-Minute Antigen Test Solution Toronto, Ontario–(Newsfile Corp. – May 21, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma”
Therma Bright Enters into Agreement to Distribute a 15 Minute Rapid COVID-19 Antibody Test
Toronto, Ontario–(Newsfile Corp. – May 6, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ COVID-19 Rapid Antigen Saliva
Newsletter: Our Vision For A Better & Brighter Future
Smart-enabled AcuVid™ Antigen Test On April 28, 2021, Therma Bright announced a memorandum of understanding (MOU) agreement to incorporate a secure tracking technology into its
